Jasmine Alsukhon, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,188, 4.1 times the $533 reported in 2021.
Across 251 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$1K
- Sanofi$963
- AstraZeneca$957
- CSL Behring$619
- Genentech USA, Inc.$382
- plus $1K from 20 others
What the payments were for
- Food & beverage$6,14999%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 32 | $1,036 |
| GSK | 45 | $1,006 |
| Sanofi | 34 | $963 |
| AstraZeneca | 47 | $957 |
| CSL Behring | 20 | $619 |
| Genentech USA, Inc. | 22 | $382 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $342 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $218 |
| Novartis | 3 | $79 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Biocryst US Sales Co., LLC | 3 | $73 |
| Octapharma USA, Inc. | 3 | $66 |
| Grifols USA, LLC | 2 | $54 |
| ADMA Biomanufacturing LLC | 1 | $51 |
| Amgen | 2 | $51 |
| Optinose US, Inc. | 2 | $42 |
| Hospira, Inc. | 1 | $32 |
| Alk-abello, Inc | 1 | $29 |
| Paratek Pharmaceuticals, Inc. | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| Cycle Pharmaceuticals Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,224 in reported general payments places this provider in the 65th percentile of 22 allergy providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirazyrIcatibant Acetate | 15 | $1,035,179 |
| TakhzyroLanadelumab-Flyo | 11 | $579,786 |
| OrladeyoBerotralstat Hydrochloride | 13 | $535,337 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $16,944 |
| Fluticasone Propionate | 66 | $1,065 |
| Ipratropium Bromide | 26 | $1,049 |
| Azelastine Hcl | 25 | $641 |
| Famotidine | 30 | $450 |
| Hydroxyzine Hcl | 17 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Firazyr, Takhzyro | $342 | $1,614,96526 claims |
| Biocryst US Sales Co., LLCOrladeyo | $73 | $535,33713 claims |
| GSKTrelegy Ellipta | $1,006 | $16,94413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 22 allergy providers in Michigan.
Other allergy in Novi
- Chad MayerFarmington Hills$25K
- Ravinder PolasaniJackson$18K
- Mutee AbdeljaberCaro$12K
- James McClellanTraverse City$11K
- Elena LewisPortage$11K
- Byra ReddySaint Joseph$9K
- Seshagiri DandamudiBattle Creek$7K
- Claire WardTraverse City$3K
- Lokesh EdaraBattle Creek$3K
- Anna DobrackiBrighton$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.